BiovaxID: Additional Phase II data

Accentia's Biovest International Inc. (OTCQB:BTVI, Tampa Fla.) subsidiary reported additional data from a Phase II trial in 26 treatment-naïve patients with MCL showing that BiovaxID led to median pr...